Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and ...

Cidara Therapeutics, a US biotech leveraging its Cloudbreak platform for next‑generation antivirals, saw its stock more than ...

Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and mortality. Current ...

Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo End of Phase 2 meeting request has ...

Shares of San Diego-based Cidara Therapeutics Inc. (NASDAQ:CDTX) were trading at $40.41, up $19.39, or 92%, on positive top-line results from its randomized, double-blind, placebo-controlled phase IIb ...

Latvia reports its first H5N1 avian flu outbreak in a backyard flock of 98 hens, joining other European countries ...

2018 Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness Curr Opin Immunol 53:38–44 Google Scholar; 18. Wu N. C. Ellebedy A. H; 2024 ...

The following is a summary of “Expert consensus on the benefits of neuraminidase in conventional influenza vaccines: a Delphi study,” published in the January 2025 issue of Infectious Disease by ...

Influenza B Market Outlook 2024-2034: The influenza B market size reached a value of USD 6.3 Million in 2023.Looking forward, the market is expected to reach USD 42.5 Million by 2034, exhibiting a ...